학술논문
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Document Type
Article
Author
Source
Subject
*CYTOKINE release syndrome
*DIFFUSE large B-cell lymphomas
*CHIMERIC antigen receptors
*CUTANEOUS T-cell lymphoma
*T cells
*
*
*
*
Language
ISSN
1042-8194
Abstract
A study conducted at the Mayo Clinic examined the association between cytokine release syndrome (CRS) and neurotoxicity (NT) with the efficacy of anti-CD-19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma. The study found that CRS and NT were common adverse events associated with CAR-T therapy, and there was a significant association between the presence of CRS and NT. However, the study also noted that the relationship between efficacy and toxicity was complex and further investigation is needed. The study analyzed patient data from 113 individuals treated with CAR-T therapy at the Mayo Clinic. This study examined the association between therapy response, toxicity, and survival outcomes in patients with aggressive lymphoma treated with CAR-T cell therapy. The results showed that while CRS and NT were associated with improved treatment-related efficacy outcomes, they were not necessary for therapeutic efficacy. Patients with low-grade CRS had better overall survival outcomes compared to those with no CRS or high-grade CRS. The study suggests that future CAR-T cell therapy development should focus on maximizing disease response while minimizing adverse events. [Extracted from the article]